Laddar...
Design and Synthesis of Type IV Inhibitors of BRAF Kinase that block dimerization and overcome paradoxical MEK/ERK activation
Despite the clinical success of BRAF inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through “paradoxical MEK/ERK signaling” where transactivation of one protomer occurs as a result of drug inhibition of the other partner in the activated dimer. The importance of...
Sparad:
| I publikationen: | J Med Chem |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6750704/ https://ncbi.nlm.nih.gov/pubmed/30977659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b01288 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|